Clinical trial
A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.
NCT06579105 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIb, Randomized, Double-blind, Placebo-controlled and Open-label Active Comparator Study to Evaluate the Efficacy, Safety, and Tolerability of AZD5004 in Adults With Type 2 Diabetes Mellitus.
- Lead sponsor
- AstraZeneca
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- October 8, 2024
- Completion date
- December 19, 2025
- Enrollment
- 406 (actual)
- Sites
- 97
Conditions
As the registry lists them; a condition with its own page is linked.